Animal Parasiticides Market Analysis & Forecast: 2026-2033
The global animal parasiticide market size is estimated to increase from USD 12.9 Bn in 2026 to USD 19.5 Bn by 2033, with a compound annual growth rate (CAGR) of 6.1%. The main factors contributing to this growth include the increasing incidence of parasitic infections in pets as well as livestock animals, increasing number of livestock animals, increasing consumption of meat and dairy products, and advancements in the field of veterinary care and animal health care programs. Parasitic infections are common in pets, with approximately 25% of dogs and cats worldwide carrying at least one intestinal parasite at any given time.
Endectocides are expected to hold the highest market share in the animal parasiticides industry in 2026, accounting for about 43.8% of the total market share. This is because of the wide range of efficacy offered by endectocides against both internal parasites (like nematodes and intestinal worms) and external parasites such as ticks, mites, and lice. This property makes it possible for producers to treat their animals against various types of parasitic attacks with one type of product, thus reducing labor cost and treatment expenses.
In September 2025, Elanco Animal Health announced that Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) surpassed USD 100 million in net sales within eight months of launch.
To learn more about this report, Request Free Sample
The Livestock segment is anticipated to contribute the highest share to the global animal parasiticides market, with an estimated revenue share of around 67.5% in 2026. This can be attributed to the fact that protecting livestock animals such as cattle, pigs, poultry, and sheep from parasitic infestation is essential for their growth and production of quality meat and milk products.
The growth in the number of commercial farms and increasing demands for protein-based foods from animals is adding impetus to the use of parasiticides. Various governments and veterinary authorities across the globe keep encouraging practices aimed at disease prevention.
In December 2025, MSD Animal Health announced that the U.S. FDA granted conditional approval for EXZOLT CATTLE-CA1 (fluralaner topical solution) for the prevention and treatment of New World screwworm infestations and for the treatment and control of cattle fever tick in livestock.
Veterinary hospitals & clinics are expected to contribute the highest market share of around 46.8% towards the total market revenues by the year 2026 due to the important position played by veterinarians when it comes to the diagnosis and treatment of parasitic diseases among livestock and companion animals, as well as preventative care.
The American Veterinary Medical Association (AVMA) reports that there are more than 130,000 licensed veterinarians in the US, with many of them being involved in the practice of providing health care services for pets and livestock. Veterinarians have been regarded as the most trusted advisors for advice on parasite prevention, which increases the demand for prescription parasiticides.
Increasing global demands for meat and dairy products mean that there will be a greater need for effective parasite treatment in animals. Parasites contribute to reduced feed efficiency, poor weight gains, fertility problems, and low milk yield, all of which result in considerable financial loss. In line with efforts to increase production levels and maintain herd health, there has been increased use of animal parasiticides.
According to the Food and Agriculture Organization (FAO), global meat production exceeded 370 million tonnes in 2024, reflecting the continued expansion of livestock farming worldwide.
Rising pet ownership globally is increasing demand for parasite prevention products. Pet owners have become more concerned about the health dangers of fleas, ticks, heartworms, and other internal parasites in their animals. As a result, people are now willing to spend money on preventative care. Veterinary organizations continue to recommend year-round parasite protection to reduce disease risks. This trend is aided by the development of new formulations such as oral pills and topicals.
According to the American Pet Products Association (APPA), Americans spent approximately USD 157 billion on their pets in 2025, with veterinary care and pet health products representing one of the fastest-growing expenditure categories.
|
Current Event |
Description and its Impact |
|
2025–2026 Expansion of Livestock Disease Control and Biosecurity Programs |
|
|
Growing Regulatory Scrutiny on Antiparasitic Resistance |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
The North American region will hold a share of 36.5% in the global animal parasiticides market by 2026, due to a high amount of veterinary healthcare spending, wide acceptance of preventive measures against parasitism, and availability of a significant number of companion animals and livestock in the region.
Another reason is that this region boasts one of the world's biggest livestock industries. The US Department of Agriculture reports that there were about 86.2 million head of cattle and calves in the United States in 2026, creating high demand for parasiticides for livestock. New product developments have further enhanced the market potential.
The Asia Pacific region is expected to be the fastest-growing regional market from 2026–2033 with a growth rate of around 7.0% on account of higher livestock production, growing pet population, animal health consciousness, and enhanced veterinary facilities in the emerging economies. India’s pet population exceeds 42 million, with dogs accounting for nearly 37 million of the total.
The region is home to the world's largest livestock population. According to the statistics from Food and Agriculture Organization (FAO), more than 50 percent of pigs are located in Asia together with the considerable number of the worlds' population of poultry and cattle, which generates a lot of demand for the products that control parasites. Such countries as China and India still strive to boost their livestock productivity.
The animal parasiticides market in the U.S. will experience growth during the forecast period. This growth can be attributed to factors such as increase in pet ownership, growth in spending on veterinary care, rise in awareness regarding zoonotic diseases, and presence of the largest livestock industry in the world. Pet ownership in the U.S. has risen substantially over the past three decades, with 66% of households, about 86.9 million homes, owning a pet as of 2024.
China is forecasted to be among the most significant markets in the global animal parasiticides market over the forecast period. Factors that will drive the market growth include increased livestock production, increased pet ownership, greater awareness about animal health, and food safety efforts made by the government.
In November 2025, Zoetis announced additional international approvals and label expansions for Simparica Trio, a broad-spectrum parasiticide that protects against fleas, ticks, heartworm disease, and intestinal parasites in dogs.
Some of the major key players in Animal Parasiticides are Zoetis Inc., Boehringer Ingelheim, Elanco Animal Health, Merck Animal Health, Bayer, Vetoquinol, Ceva Sante Animale, Neogen Corporation, Dechra Pharmaceuticals, Heska Corporation, Norbrook Laboratories and Idexx Laboratories.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 12.9 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.1% | 2033 Value Projection: | USD 19.5 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Zoetis Inc., Boehringer Ingelheim, Elanco Animal Health, Merck Animal Health, Bayer, Vetoquinol, Ceva Santé Animale, Neogen Corporation, Dechra Pharmaceuticals, Heska Corporation, Norbrook Laboratories and Idexx Laboratories |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
